Ubs Group Ag Aptevo Therapeutics Inc. Transaction History

Ubs Group Ag

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	SELL	$0.17 - $0.38 $13 - $30	-80 Reduced 94.12%	5 $0
Q3 2023 Nov 09, 2023	BUY	$0.31 - $1.78 $26 - $151	85 New	85 $0
Q4 2022 Feb 08, 2023	BUY	$2.0 - $138.16 $2,000 - $138,160	1,000 Added 232.56%	1,430 $3,000
Q3 2022 Nov 10, 2022	SELL	$3.12 - $142.56 $2,112 - $96,513	-677 Reduced 61.16%	430 $1,000
Q2 2022 Aug 10, 2022	BUY	$3.26 - $6.3 $3,608 - $6,974	1,107 New	1,107 $4,000
Q1 2022 May 16, 2022	SELL	$4.48 - $8.42 $14,389 - $27,045	-3,212 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$6.48 - $17.49 $20,813 - $56,177	3,212 New	3,212 $25,000
Q3 2021 Nov 15, 2021	SELL	$15.01 - $22.16 $27,333 - $40,353	-1,821 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$21.85 - $30.0 $39,788 - $54,630	1,821 New	1,821 $41,000
Q1 2021 May 12, 2021	SELL	$27.86 - $40.59 $8,664 - $12,623	-311 Closed	0 $0
Q4 2020 Feb 11, 2021	SELL	$6.21 - $48.36 $53,014 - $412,849	-8,537 Reduced 96.49%	311 $11,000
Q3 2020 Nov 12, 2020	SELL	$7.21 - $9.37 $8,414 - $10,934	-1,167 Reduced 11.65%	8,848 $67,000
Q2 2020 Jul 31, 2020	SELL	$3.11 - $9.27 $4,767 - $14,210	-1,533 Reduced 13.28%	10,015 $83,000
Q1 2020 May 01, 2020	BUY	$3.29 - $9.73 $37,992 - $112,362	11,548 New	11,548 $43,000

Ticker APVO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 5,090,640
Market Cap $22.4M
Description
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelo...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.